The government continues to streamline infrastructure delivery in New Zealand, with the latest announcement ... up our infrastructure capability, says EMA Head of Advocacy Alan McDonald.
Operator Welcome to Amarin Corporation's conference call to discuss its fourth-quarter and full-year 2024 business update and ...
DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
The new logo – which consists of a yellow number 5 on a blue background – will be used by the channel from today (Wednesday 12th March) onwards. It comes after the broadcaster announced that ...
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
From funding challenges to what changes in joint drug procurement: Here’s what you need to know about the new rules aimed at ...
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat, in phase ...
One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti. BCMA-directed cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback